NYMC Faculty Publications
A Brief History of OspA Vaccines Including Their Impact on Diagnostic Testing for Lyme Disease
Author Type(s)
Faculty
DOI
10.1016/j.diagmicrobio.2021.115572
Journal Title
Diagnostic Microbiology and Infectious Disease
First Page
115572
Document Type
Article
Publication Date
1-1-2022
Department
Medicine
Abstract
The only United States Food and Drug Administration approved vaccine preparation to prevent Lyme disease consisted of a single recombinant outer surface protein A (OspA), which was marketed for use from late 1998 until early 2002, with no vaccine currently available for humans for nearly 20 years. OspA vaccines generate an antibody-mediated, transmission blocking immunity, that prevents Borrelia burgdorferi from being transmitted during a tick bite. Although this OspA vaccine was safe and effective, it likely would have required booster doses to maintain immunity, and vaccination regularly caused false positive results on first-tier serologic testing for Lyme disease, when a whole cell-based enzyme immunoassay was used. Clinical trials are in progress to test a new multivalent OspA vaccine designed to prevent Lyme disease in both the United States and Europe.
Recommended Citation
Wormser, G. P. (2022). A Brief History of OspA Vaccines Including Their Impact on Diagnostic Testing for Lyme Disease. Diagnostic Microbiology and Infectious Disease, 102 (1), 115572. https://doi.org/10.1016/j.diagmicrobio.2021.115572
